Drug intelligence / Profile preview

kylo-0603

Development stage: Phase 1
Lead developer: Kylonova Biopharma
Modality: Small Molecules
Administration: Oral

Overview

Kylo-0603 is an investigational small molecule drug that acts as a thyroxine receptor beta (THR-β) agonist. It is being developed primarily for the treatment of non-alcoholic steatohepatitis (NASH), with additional clinical investigation in related liver diseases such as alcoholic hepatitis and fatty liver disease. Kylo-0603 is designed to selectively target THR-β, which plays a key role in regulating lipid metabolism and reducing hepatic fat accumulation, making it a promising candidate for metabolic liver disorders. The developer of Kylo-0603 is Kylonova (Xiamen) Biopharma Co., Ltd., with some sources also mentioning Shanghai Hegia Biomedicine Co., Ltd.

Targets

THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on kylo-0603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kylo-0603.

Explore the full profile